1. Informed Consent in Phase I Oncology Trials (Core Standard)

Phase I oncology trials are primarily designed to:

• Determine safety and toxicity
• Establish maximum tolerated dose (MTD)
• Study pharmacokinetics, not efficacy

So legally and ethically:

The central risk is not only physical harm but misunderstanding of purpose

A. Key Legal Requirements (Modern Standard)

Across US (Common Rule), UK (Montgomery standard influence), and international ethics (Declaration of Helsinki), consent must include:

1. Purpose disclosure

• “This is research, not treatment”
• “Primary goal is safety, not cure”

2. Risk disclosure

• Death risk (sometimes first-in-human agents)
• Severe toxicity (organ failure, cytokine storm, etc.)
• Unknown long-term effects

3. Therapeutic misconception warning

Patients must understand:

• Participation ≠ individualized therapy
• Benefit is uncertain and often low in Phase I

4. Alternatives

• Palliative care
• Standard chemotherapy (if any remains)
• Hospice or supportive care

5. Voluntariness

• No coercion due to desperation
• No overstated hope by clinicians

B. Core Ethical Problem in Phase I Oncology

Two recurring issues:

1. Therapeutic misconception

Patients believe:

“This trial is designed to treat me personally”

2. Therapeutic misestimation

Patients understand “research” but:

Overestimate chance of benefit

2. Landmark Case Laws (Detailed)

CASE 1: Canterbury v Spence (USA, 1972)

Facts

A patient underwent spinal surgery and became paralyzed. The doctor had not disclosed the risk of paralysis.

Legal Issue

Should disclosure depend on professional medical custom or patient needs?

Judgment

Court rejected doctor-centered disclosure standards.

Rule Established

Doctors must disclose:

Risks that a “reasonable patient” would consider significant

Importance for Phase I Oncology

This case established modern informed consent autonomy principle:

• Doctors must disclose even low-probability catastrophic risks
• In Phase I trials, this includes:
  • death risk from first-in-human drugs
  • severe organ toxicity

CASE 2: Montgomery v Lanarkshire Health Board (UK, 2015)

Facts

A diabetic mother was not informed of a risk of shoulder dystocia during delivery.

Judgment

Court ruled doctors must disclose material risks regardless of medical judgment.

Legal Principle

Materiality is judged by the patient’s perspective, not physician’s discretion

Importance for Phase I Oncology

Direct implications:

• Doctors must explain trial purpose clearly
• Must disclose:
  • low probability but serious risks
  • absence of guaranteed benefit
• Reinforces rejection of paternalism in oncology consent

CASE 3: Johnson v Kokemoor (USA, 1996)

Facts

A surgeon failed to disclose his limited experience in performing complex aneurysm surgery.

Issue

Is physician experience part of informed consent?

Judgment

Court held:

• Surgeon’s experience is a material factor

Rule

Patients must be informed of:

• surgeon’s experience level
• comparative risk differences

Importance for Phase I Oncology

Applies strongly to:

• first-in-human trials
• novel immunotherapies
• gene therapy Phase I studies

Consent must include:

• institutional experience with protocol
• investigator learning curve

CASE 4: Truman v Thomas (California, USA, 1980)

Facts

A patient repeatedly refused Pap smear tests due to cost concerns. Doctor did not adequately warn of cancer risk.

Judgment

Court held physician had duty to ensure patient understood consequences of refusal.

Rule Established

Consent includes:

Duty to inform about consequences of not participating or refusing care

Importance for Phase I Oncology

Requires disclosure of:

• consequences of NOT enrolling:
  • disease progression
  • lack of remaining standard therapies
• but must avoid coercion (“no treatment left so join trial” pressure)

CASE 5: Salgo v Leland Stanford (USA, 1957)

Facts

A patient underwent aortography and became paralyzed. Risks were not properly disclosed.

Judgment

Court introduced the term “informed consent” into law.

Rule

Doctors must disclose:

• facts necessary for intelligent consent
• risks of the procedure

Importance for Phase I Oncology

This is the foundation case for all oncology trial consent law:

• established legal recognition of consent duty
• later expanded by Canterbury and Montgomery

CASE 6: Schloendorff v Society of New York Hospital (USA, 1914)

Facts

A patient consented to examination under anesthesia but refused surgery; doctors still operated.

Judgment

Judge Cardozo stated:

“Every human being of adult years and sound mind has the right to determine what shall be done with their own body.”

Rule Established

• Any unauthorized medical procedure = battery

Importance for Phase I Oncology

In trials:

• enrollment without valid informed consent = legal battery
• reinforces strict requirement for voluntary participation

CASE 7: Grimes v Kennedy Krieger Institute (USA, 2001)

Facts

Children were exposed to lead in research without adequate disclosure of risks.

Judgment

Court emphasized:

• research ethics cannot be lower than clinical care standards

Rule

• researchers owe heightened duty of protection
• especially vulnerable populations

Importance for Phase I Oncology

Applies to:

• terminal cancer patients considered “vulnerable”
• requires:
  • enhanced clarity
  • avoidance of therapeutic illusion

CASE 8: Chester v Afshar (UK, 2004)

Facts

Patient was not warned of small risk of paralysis from spinal surgery.

Judgment

Even though surgery was properly performed:

• failure to warn = liability

Legal Principle

Loss of autonomy itself is actionable harm

Importance for Phase I Oncology

Means:

• even if trial is conducted properly
• failure to disclose:
  • low probability fatal risks
  • uncertainty of benefit
    → can still lead to liability

3. Combined Legal Principles for Phase I Oncology Consent

Across all cases, courts consistently establish:

A. Patient autonomy is central

• Schloendorff → bodily autonomy foundation
• Montgomery → modern patient-centered model

B. Risk disclosure is patient-defined

• Canterbury + Montgomery → materiality standard

C. Research does NOT reduce ethical duty

• Grimes → research subjects deserve full protection

D. Even rare risks must be disclosed

• Chester + Salgo → failure to warn is actionable

E. Authority or expertise does NOT override disclosure

• Johnson v Kokemoor → experience must be disclosed

4. What This Means Practically for Phase I Oncology Trials

A legally sound consent process must ensure patients understand:

1. Nature of the study

• Safety and dose-finding, not treatment

2. Low probability of benefit

• Benefit is uncertain and often minimal

3. High uncertainty

• First-in-human risks may be unknown

4. Full risk spectrum

• death
• organ toxicity
• long-term unknown effects

5. Alternatives

• standard care
• palliative care
• no treatment

6. Investigator disclosure

• experience level
• institutional familiarity with protocol

5. Key Takeaway

Phase I oncology consent is legally treated as:

A high-autonomy, high-uncertainty decision environment where courts strongly favor patient-centered disclosure over physician judgment